Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence

被引：0

作者：

Sanz, Miguel A.

Fenaux, Pierre ^{[10
]}

Lo Coco, Francesco ^{[1
]}

Amadori, Sergio ^{[1
]}

Buchner, T. ^{[2
]}

Burnett, Alan K. ^{[3
]}

Cimino, Giuseppe ^{[4
]}

Doehner, H. ^{[5
]}

Dombret, Herve ^{[6
]}

Lengfelder, E. ^{[7
]}

Lowenberg, Bob ^{[8
]}

Ludwig, H. ^{[9
]}

Sanz, Miguel ^{[11
]}

机构：

[1] Univ Tor Vergata, Rome, Italy

[2] Univ Klinikum Munster, Munster, Germany

[3] Cardiff Univ, Cardiff, Wales

[4] Univ Roma La Sapienza, Rome, Italy

[5] Univ Klinikum Ulm, Ulm, Germany

[6] Hop St Louis, Inst Univ Hematol, Paris, France

[7] Univ Klinikum Mannheim, Mannheim, Germany

[8] Eramus Univ Hosp Rotterdam Drikzigt, Rotterdam, Netherlands

[9] Wilhelminenspital Stadt Wien, Vienna, Austria

[10] Univ Paris 13, Paris, France

[11] Hosp Univ La Fe, Valencia, Spain

来源：

HAEMATOLOGICA | 2005年 / 90卷 / 09期

关键词：

arsenic trioxide; acute promyelocytic leukemia;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recent studies have demonstrated the beneficial effects of arsenic trioxide (ATO) in the treatment of relapsed acute promyelocytic leukemia (APL). The aim of this review is to discuss the role of ATO in the management of APL. Based on the available clinical evidence, a tentative algorithm is proposed for the treatment of patients who relapse after or are refractory to all trans-retinoic acid-based therapy. Other opportunities for the use of ATO in front-line treatment of APL are also discussed, especially its potential use in patients at high risk of relapse and in those with contraindications to chemotherapy or in whom the amount of chemotherapy should be reduced.

引用

页码：1231 / 1235

页数：5

共 37 条

[1] Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy [J].